http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
PureTech Announces Annual Results for Year Ended December 31, 2024
-
PureTech Health: Notice of Results
-
PureTech Appoints Peel Hunt as Joint UK Corporate Broker
-
PureTech Health Plc (PRTC) Appoints Robert J. Hombach to its Board
-
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
-
PureTech to Present at the Leerink Partners Global Healthcare Conference
-
PureTech (PRTC) Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with Glyp
-
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Pla
-
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
-
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
-
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
-
PureTech Appoints UBS as UK Corporate Broker
-
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondar
-
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
-
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
-
PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
-
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
-
PureTech to Present at Two Upcoming Investor Conferences
-
PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
-
PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting
-
PureTech to Present at CHEST 2024 Annual Meeting
-
PureTech Health Plc (PRTC) -Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
-
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
-
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
-
PureTech Health plc – Half-Year Report
-
PureTech Appoints Michele Holcomb, PhD, to Board of Directors
-
PureTech Health: Notice of Half-Yearly Results
-
PureTech Health-founded (PRTC) Seaport Therapeutics Appoints David Wheadon to its Board
-
PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors
-
PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
-
PureTech Health: Completion of Tender Offer & Total Voting Rights
-
PureTech Health: Results of the Tender Offer
-
PureTech Health Plc (PRTC) Appoints Raju Kucherlapati as Board Chair
-
PureTech Announces Change of Board Role
-
PureTech Health Plc (PRTC) Founded Entity Seaport Therapeutics Appoints Management Executives
-
PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team
-
PureTech Health: Results of Annual General Meeting
-
PureTech Health: Result of General Meeting
-
PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
-
PureTech to Present at the Jefferies Global Healthcare Conference
-
PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
-
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
-
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
-
PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
-
PureTech Announces Annual Results for Year Ended December 31, 2023
-
PureTech Health: Notice of Results
-
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
-
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
-
PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
-
PureTech Health Plc (PRTC) Announces Proposed $100M Capital Return

